AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35659905 — intervention group
Group type: EXPERIMENTAL
Intervention: LACTIN-V (Lactobacillus crispatus CTV-05)
Number of subjects: 66
Study 35659905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 33098255 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 1600
Study 33098255 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain CT
Number of subjects: 1600
Study 33098255 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 1600
Study 33098255 — intervention group
Group type: EXPERIMENTAL
Intervention: NSE
Number of subjects: 1600
Study 33098255 — intervention group
Group type: EXPERIMENTAL
Intervention: S-100β
Number of subjects: 1600
Study 33098255 — intervention group
Group type: EXPERIMENTAL
Intervention: SSEP
Number of subjects: 1600
Study 33098255 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG
Number of subjects: 1600
Study 33098255 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain stem reflex
Number of subjects: 1600
Study 33098255 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor response
Number of subjects: 1600
Study 33098255 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoclonus
Number of subjects: 1600
Study 33098255 — intervention group
Group type: EXPERIMENTAL
Intervention: GWR value < 1.1
Number of subjects: 1600
Study 33098255 — intervention group
Group type: EXPERIMENTAL
Intervention: Status epilepticus
Number of subjects: 1600
Study 33098255 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst suppression
Number of subjects: 1600
Study 33098255 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 1600
Study 33098255 — intervention group
Group type: EXPERIMENTAL
Intervention: NSE and S-100 knowledge
Number of subjects: 1600
Study 33098255 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of neurological prognostication
Number of subjects: 1600
Study 32546129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Suicide Prevention for psychosis (CBSPp) plus Treatment As Usual (TAU)
Number of subjects: 250
Study 32546129 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU) alone
Number of subjects: 250
Study 34270810 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33212328 — intervention group
Group type: EXPERIMENTAL
Intervention: BuzzyⓇ device
Number of subjects: 219
Study 33212328 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine patch
Number of subjects: 219
Study 35320164 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic resistance group C
Number of subjects: 102
Study 35320164 — intervention group
Group type: COMPARATOR
Intervention: Aerobic group A
Number of subjects: 102
Study 35320164 — intervention group
Group type: COMPARATOR
Intervention: Resistance group B
Number of subjects: 102
Study 32174343 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient safety dashboard
Number of subjects: 0
Study 32174343 — intervention group
Group type: COMPARATOR
Intervention: Electronic health record
Number of subjects: 0
Study 34995827 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 171
Study 34995827 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (no-EVT)
Number of subjects: 171
Study 33950535 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 283
Study 33950535 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (BUP-NX)
Number of subjects: 283
Study 33166482 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer comparisons intervention group
Number of subjects: 88
Study 33166482 — intervention group
Group type: COMPARATOR
Intervention: Control group (individual feedback only)
Number of subjects: 88
Study 35260342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (loading dose 400 mg/m2 day 1; subsequent weekly 250 mg/m2 doses until two weeks postradiotherapy) + Cisplatin (75 mg/m2) + Pemetrexed (500 mg/m2) + Radiotherapy (maximally 66 Gy starting on day 22)
Number of subjects: 106
Study 33064597 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrazine at concentrations of 2, 4, 8, 16, and 32 mg L‐1
Number of subjects: 147
Study 33064597 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrazine at concentrations of 0.18, 6, 12, and 18 mg L‐1 after air exposition stress
Number of subjects: 147
Study 33064597 — intervention group
Group type: COMPARATOR
Intervention: Control group (without herbicide)
Number of subjects: 147
Study 33064597 — intervention group
Group type: COMPARATOR
Intervention: Control group with solubility adjuvant (acetone)
Number of subjects: 147
Study 32338756 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplements
Number of subjects: 197
Study 32338756 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat consumption more than twice a week for dinner
Number of subjects: 197
Study 616858955 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing pattern with a postexhalation rest period
Number of subjects: 40
Study 616858955 — intervention group
Group type: COMPARATOR
Intervention: Breathing pattern without a postexhalation rest period
Number of subjects: 40
Study 36332676 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention delivered by mobile application (APP), 5 sessions at weeks 2, 4, 6, 8, and 12 after discharge
Number of subjects: 98
Study 36332676 — intervention group
Group type: COMPARATOR
Intervention: Routine telephone counselling provided by follow-up nurses at the 12th week after discharge
Number of subjects: 98
Study 34330854 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-Up program (combined exercise and education)
Number of subjects: 74
Study 34330854 — intervention group
Group type: COMPARATOR
Intervention: Usual physical therapy (control)
Number of subjects: 74
Study 32580724 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate sleep diagnostics and intervention (TAU+SI-T0)
Number of subjects: 0
Study 32580724 — intervention group
Group type: COMPARATOR
Intervention: Delayed start of sleep intervention (TAU+SI-T1; 6 months after inclusion)
Number of subjects: 0
Study 36064612 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 25
Study 36064612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 33259976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine throat spray
Number of subjects: 26
Study 33259976 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized lidocaine
Number of subjects: 26
Study 33259976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine throat spray and nebulized lidocaine
Number of subjects: 26
Study 33259976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 33171589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod Protein Hydrolysate (CPH) 4 g protein
Number of subjects: 30
Study 33171589 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 g protein)
Number of subjects: 30
Study 35322077 — intervention group
Group type: EXPERIMENTAL
Intervention: favipiravir
Number of subjects: 150
Study 35322077 — intervention group
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Number of subjects: 150
Study 35322077 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 150
Study 32890650 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid revascularization within 3 months after diagnosis
Number of subjects: 795512
Study 32890650 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid revascularization rates over time
Number of subjects: 795512
Study 32890650 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-specific carotid revascularization rates
Number of subjects: 795512
Study 32890650 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician characteristics associated with higher revascularization rates
Number of subjects: 795512
Study 32890650 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of surgeon types
Number of subjects: 795512
Study 35138634 — intervention group
Group type: EXPERIMENTAL
Intervention: AuraGain™
Number of subjects: 100
Study 35138634 — intervention group
Group type: COMPARATOR
Intervention: i-gel™
Number of subjects: 100
Study 32519066 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel biotechnology-based strategies to reduce LDL-C, non-HDL-C, triglyceride, apolipoprotein B, and Lp(a) levels.
Number of subjects: 0
Study 35775451 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonists (GLP-1RAs)
Number of subjects: 0
Study 35775451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is)
Number of subjects: 0
Study 35775451 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 34432829 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation at ≥16 weeks GA
Number of subjects: 10231
Study 34432829 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation at ≥24 weeks GA
Number of subjects: 10231
Study 34432829 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 10231
Study 34432829 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher parity (1-4 births)
Number of subjects: 10231
Study 34432829 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher parity (five or more births)
Number of subjects: 10231
Study 34432829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower educational attainment (primary)
Number of subjects: 10231
Study 34432829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower educational attainment (secondary)
Number of subjects: 10231
Study 34432829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower educational attainment (university)
Number of subjects: 10231
Study 34432829 — intervention group
Group type: EXPERIMENTAL
Intervention: Contributing to household income
Number of subjects: 10231
Study 34432829 — intervention group
Group type: EXPERIMENTAL
Intervention: History of spontaneous abortion
Number of subjects: 10231
Study 34432829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy testing
Number of subjects: 10231
Study 34432829 — intervention group
Group type: EXPERIMENTAL
Intervention: Residing in the same district as the health facility
Number of subjects: 10231
Study 34432829 — intervention group
Group type: EXPERIMENTAL
Intervention: Residing in the same catchment area as the health facility
Number of subjects: 10231
Study 34432829 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior preterm delivery
Number of subjects: 10231
Study 34432829 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior low birthweight delivery
Number of subjects: 10231
Study 34432829 — intervention group
Group type: EXPERIMENTAL
Intervention: No obstetric history
Number of subjects: 10231
Study 33201033 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI)
Number of subjects: 4760
Study 33201033 — intervention group
Group type: COMPARATOR
Intervention: No Traumatic Brain Injury (Control)
Number of subjects: 4760
Study 33201033 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI) in men aged 60 to 70
Number of subjects: 4760
Study 33201033 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI) in men aged 71 to 80
Number of subjects: 4760
Study 33201033 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI) in women aged 81 to 90
Number of subjects: 4760
Study 36484664 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteotome technique
Number of subjects: 30
Study 36484664 — intervention group
Group type: COMPARATOR
Intervention: Conventional drilling (control group)
Number of subjects: 30
Study 33727656 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk populations (CK, LIA, CIR, LT)
Number of subjects: 400
Study 33727656 — intervention group
Group type: COMPARATOR
Intervention: Blood donors (BD)
Number of subjects: 400
Study 33727656 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sample
Number of subjects: 400
Study 35017305 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK 0.25 mg/kg
Number of subjects: 137
Study 35017305 — intervention group
Group type: COMPARATOR
Intervention: TNK 0.40 mg/kg
Number of subjects: 137
Study 35017305 — intervention group
Group type: COMPARATOR
Intervention: Alteplase 0.90 mg/kg
Number of subjects: 137
Study 34391509 — intervention group
Group type: EXPERIMENTAL
Intervention: Stockholm3 score of 0.11 or higher
Number of subjects: 2293
Study 34391509 — intervention group
Group type: COMPARATOR
Intervention: PSA of 3 ng/mL or higher
Number of subjects: 2293
Study 34391509 — intervention group
Group type: EXPERIMENTAL
Intervention: Stockholm3 score of 0.11 or higher combined with MRI-targeted and systematic biopsies
Number of subjects: 2293
Study 34391509 — intervention group
Group type: EXPERIMENTAL
Intervention: Stockholm3 score of 0.15 or higher
Number of subjects: 2293
Study 35771361 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg citalopram
Number of subjects: 24
Study 35771361 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg reboxetine
Number of subjects: 24
Study 35771361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33687926 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ACL reconstruction
Number of subjects: 167
Study 33687926 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation followed by optional delayed ACL reconstruction
Number of subjects: 167
Study 35739299 — intervention group
Group type: EXPERIMENTAL
Intervention: VOR/HCQ
Number of subjects: 42
Study 35739299 — intervention group
Group type: COMPARATOR
Intervention: RGF
Number of subjects: 42
Study 33818933 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoprosin (once a day for three months)
Number of subjects: 60
Study 33818933 — intervention group
Group type: COMPARATOR
Intervention: Alpha-blockers and fluoroquinolones (control group)
Number of subjects: 60
Study 35675032 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg/kg
Number of subjects: 34
Study 35675032 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 0.3 mg/kg
Number of subjects: 34
Study 36296952 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and vegetables containing phenylalanine 76−100 mg/100 g, additional intake of 50 mg/day and then 100 mg/day
Number of subjects: 16
Study 36296952 — intervention group
Group type: COMPARATOR
Intervention: Milk protein sources, additional intake of 50 mg/day and then 100 mg/day
Number of subjects: 16
Study 32293929 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-level cluster-randomized design
Number of subjects: 0
Study 32293929 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation methods
Number of subjects: 0
Study 32293929 — intervention group
Group type: EXPERIMENTAL
Intervention: R package PowerUpR and its Shiny application
Number of subjects: 0
Study 32032651 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM at 33°C
Number of subjects: 696
Study 32032651 — intervention group
Group type: COMPARATOR
Intervention: TTM at 36°C
Number of subjects: 696
Study 32032651 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 696
Study 32032651 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (after correction for confounders)
Number of subjects: 696
Study 32032651 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (after correction for clustering within centers)
Number of subjects: 696
Study 35980349 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 128
Study 35980349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + Docetaxel
Number of subjects: 128
Study 32821924 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 1317
Study 32821924 — intervention group
Group type: COMPARATOR
Intervention: Non-caloric restriction (non-CR)
Number of subjects: 1317
Study 36108767 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine combined with insulin
Number of subjects: 40
Study 36108767 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 36108767 — intervention group
Group type: COMPARATOR
Intervention: DM group
Number of subjects: 40
Study 36108767 — intervention group
Group type: COMPARATOR
Intervention: Insulin monotherapy
Number of subjects: 40
Study 36108767 — intervention group
Group type: COMPARATOR
Intervention: NAC monotherapy
Number of subjects: 40
Study 34245368 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (0.1 mg/kg in 100 ml normal saline)
Number of subjects: 76
Study 34245368 — intervention group
Group type: COMPARATOR
Intervention: Control (100 ml normal saline)
Number of subjects: 76
Study 34157772 — intervention group
Group type: EXPERIMENTAL
Intervention: Mozart's double piano sonata exposure for 14 days, twice per day
Number of subjects: 40
Study 34157772 — intervention group
Group type: COMPARATOR
Intervention: No music exposure (control group)
Number of subjects: 40
Study 33046607 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistrain probiotics capsules (n = 34)
Number of subjects: 72
Study 33046607 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 38)
Number of subjects: 72
Study 33046607 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin levels
Number of subjects: 72
Study 33138121 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered milk
Number of subjects: 3864
Study 33138121 — intervention group
Group type: EXPERIMENTAL
Intervention: Young children milk (YCM) for ages 1-2 years and preschool children milk (PCM) for ages 3-5 years
Number of subjects: 3864
Study 33138121 — intervention group
Group type: EXPERIMENTAL
Intervention: Both scenarios (Powdered milk and YCM/PCM)
Number of subjects: 3864
Study 34018138 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention focusing on reducing caloric intake and increasing steps across the day
Number of subjects: 28
Study 34018138 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 28
Study 32568139 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of moderate-intensity cycling exercise
Number of subjects: 27
Study 32568139 — intervention group
Group type: COMPARATOR
Intervention: 40-minute rest (control group)
Number of subjects: 27
Study 32568139 — intervention group
Group type: COMPARATOR
Intervention: Comparison of RHI before exercise between groups
Number of subjects: 27
Study 32568139 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of RHI after exercise between groups
Number of subjects: 27
Study 33259163 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid suppression plus feeding modifications (4 weeks' proton pump inhibitor [PPI] + feeding modifications)
Number of subjects: 49
Study 33259163 — intervention group
Group type: COMPARATOR
Intervention: Acid suppression alone (4 weeks' proton pump inhibitor [PPI])
Number of subjects: 49
Study 33259163 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (PPI + feeding modifications and PPI alone)
Number of subjects: 49
Study 33259163 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with PPI washout
Number of subjects: 49
Study 33259163 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with continued PPI therapy
Number of subjects: 49
Study 35351537 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance-guided deep learning method for dose prediction
Number of subjects: 161
Study 35351537 — intervention group
Group type: COMPARATOR
Intervention: Mask-based methods
Number of subjects: 161
Study 35192209 — intervention group
Group type: EXPERIMENTAL
Intervention: FX CorAL
Number of subjects: 0
Study 35192209 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISIO
Number of subjects: 0
Study 35192209 — intervention group
Group type: EXPERIMENTAL
Intervention: xevonta
Number of subjects: 0
Study 33068707 — intervention group
Group type: EXPERIMENTAL
Intervention: BReF intervention
Number of subjects: 24
Study 33068707 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 24
Study 33800650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 13
Study 32583982 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D supplementation
Number of subjects: 1398
Study 32583982 — intervention group
Group type: COMPARATOR
Intervention: Marine Omega-3 Fatty Acid supplementation
Number of subjects: 1398
Study 34817631 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulorrhaphy performed (Group A)
Number of subjects: 67
Study 34817631 — intervention group
Group type: COMPARATOR
Intervention: No capsulorrhaphy performed (Group B)
Number of subjects: 67
Study 33091520 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cell (BM MNC) therapy, 200 million BM MNC's injected transendocardially after a 60 mL bone marrow aspiration.
Number of subjects: 10
Study 33091520 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cell (BM MNC) therapy
Number of subjects: 10
Study 33087156 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven implementation strategies
Number of subjects: 12
Study 33087156 — intervention group
Group type: COMPARATOR
Intervention: Control group (no data-driven implementation strategies)
Number of subjects: 12
Study 34972033 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (0.5 μg/kg/min over 20 min)
Number of subjects: 33
Study 34972033 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride over 20 min)
Number of subjects: 33
Study 34181008 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhoods with greater deprivation
Number of subjects: 97
Study 34181008 — intervention group
Group type: COMPARATOR
Intervention: Neighborhoods with lesser deprivation
Number of subjects: 97
Study 32145277 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral arm training
Number of subjects: 69
Study 32145277 — intervention group
Group type: COMPARATOR
Intervention: Unilateral arm training
Number of subjects: 69
Study 616280573 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Transtheoretical Model Intervention (ETMI)
Number of subjects: 220
Study 616280573 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy as usual (Control)
Number of subjects: 220
Study 36029019 — intervention group
Group type: COMPARATOR
Intervention: Screening for cardiovascular disease using low-dose computed tomography, limb blood pressure measurement, telemetric assessment of heart rhythm, cholesterol and HgbA1c measurements.
Number of subjects: 0
Study 36029019 — intervention group
Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 0